CVS HEALTH Corp CVS

CVS Health's strongest current source fact is scale with profit attached: the SEC EDGAR 10-Q for the period ending 2026-03-31 reports revenues of $100.43B, net income attributable to parent of $2.94B, operating income of $4.68B and diluted EPS of $2.30. That puts the daily story on a filed operating base, not on market rumour or a loose ticker summary.

The company rail is healthcare delivery, benefits and pharmacy rather than a single clean product line. The supplied 10-Q evidence says the Health Care Benefits segment's members access products and services through employer groups, government-sponsored plans or individually, and that the segment also serves customers buying products and services ancillary to its health insurance products. That matters because CVS is being read through customers, claims, pharmacy activity, consumer wellness and benefits administration, not just a shopfront name.

The balance sheet and cash facts are equally central. The 10-Q for the period ending 2026-03-31 reports assets of $252.97B, liabilities of $175.34B, stockholders' equity attributable to parent of $77.46B, cash and cash equivalents of $9.54B and short-term investments of $2.26B. Operating cash flow was $4.25B, payments to acquire property, plant and equipment were $849.0M, inventory was $17.77B, and the increase in inventories was $-1.48B. The diluted share count was 1.28B shares.

The source route here is SEC EDGAR, including the filing index, submissions JSON, companyfacts JSON, the 2026-05-06 10-Q and 8-K, the 2026-05-18 8-K, and late-May securities and insider-reporting filings. No chart route is supplied in the evidence, so this report does not claim candle patterns, support levels, volume behaviour or moving averages. The market mechanism visible from the rail is filing digestion: earnings numbers, cash conversion, balance-sheet weight, compensation approval and securities-registration filing trail.

What changed most clearly in the recent public record is the May filing cluster. CVS filed an 8-K on 2026-05-06 saying it issued a press release announcing results for the three months ended March 31, 2026. It later filed an 8-K on 2026-05-18 saying stockholders approved the 2026 Incentive Compensation Plan, replacing the expiring 2017 Incentive Compensation Plan. The evidence list also includes a 2026-05-22 S-8, a 2026-05-22 S-3ASR, a 2026-05-22 Form 144 and Form 4 filings dated 2026-05-22 and 2026-06-01.

What remains unproved by this rail is just as important. The supplied evidence does not give a current share price, valuation multiple, guidance figure, dividend detail, buyback amount, analyst view, lawsuit update, customer count or market-share change. A deeper file would need those items from named sources before making claims beyond the filed financials, segment descriptions and recent EDGAR events.